Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells
M Smollich, M Götte, J Fischgräbe, I Radke… - Anticancer …, 2009 - ar.iiarjournals.org
Background: Estrogen receptors (ER) α and β play an important role in breast cancer.
Recently, systemic adjuvant endocrine therapy with selective estrogen receptor modulator …
Recently, systemic adjuvant endocrine therapy with selective estrogen receptor modulator …
Effects of a combined treatment with tamoxifen and estrogen receptor β agonists on human breast cancer cell lines
C Lattrich, S Schüler, J Häring, M Skrzypczak… - Archives of gynecology …, 2014 - Springer
Introduction Coexpression of estrogen receptors (ER) α and β is present in about half of all
breast cancer cases. Whereas ERα is a well-established target for endocrine therapy with …
breast cancer cases. Whereas ERα is a well-established target for endocrine therapy with …
Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells
Estrogen is a risk factor of breast cancer. Elevated expression of aromatase (estrogen
synthase) in breast tissues increases local estradiol concentrations and is associated with …
synthase) in breast tissues increases local estradiol concentrations and is associated with …
[HTML][HTML] In situaromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in …
AE Lykkesfeldt, KL Henriksen, BB Rasmussen… - BMC cancer, 2009 - Springer
Background New, third-generation aromatase inhibitors (AIs) have proven comparable or
superior to the anti-estrogen tamoxifen for treatment of estrogen receptor (ER) and/or …
superior to the anti-estrogen tamoxifen for treatment of estrogen receptor (ER) and/or …
[HTML][HTML] Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison …
M Madeira, A Mattar, AF Logullo, FA Soares… - BMC cancer, 2013 - Springer
Background The role of estrogen receptor beta (ER-β) in breast cancer (BC) remains
unclear. Some studies have suggested that ER-β may oppose the actions of estrogen …
unclear. Some studies have suggested that ER-β may oppose the actions of estrogen …
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels
J Geisler, H Helle, D Ekse, NK Duong, DB Evans… - Clinical cancer …, 2008 - AACR
Purpose: To evaluate the influence of the third-generation aromatase inhibitor letrozole
(Femara) on breast cancer tissue levels of estrone (E1), estradiol (E2), and estrone sulfate …
(Femara) on breast cancer tissue levels of estrone (E1), estradiol (E2), and estrone sulfate …
Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma
SK Gruvberger-Saal, PO Bendahl, LH Saal… - Clinical Cancer …, 2007 - AACR
Purpose: Endocrine therapies, such as tamoxifen, are commonly given to most patients with
estrogen receptor (ERα)–positive breast carcinoma but are not indicated for persons with …
estrogen receptor (ERα)–positive breast carcinoma but are not indicated for persons with …
Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α
JN Ingle, J Cairns, VJ Suman, LE Shepherd… - Clinical Cancer …, 2020 - AACR
Purpose: To determine if the degree of estrogen suppression with aromatase inhibitors (AI:
anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer …
anastrozole, exemestane, letrozole) is associated with efficacy in early-stage breast cancer …
Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery
M Glaeser, D Niederacher, S Djahansouzi… - Anticancer …, 2006 - ar.iiarjournals.org
The influence of 17β-estradiol (E2), tamoxifen (TAM) and raloxifen (RLX) on the proliferation
of breast (BC) and endometrial carcinoma cell lines (EC) and the expression of different …
of breast (BC) and endometrial carcinoma cell lines (EC) and the expression of different …
Tamoxifen or aromatase inhibitors in breast cancer: efficacy and safety
P Neven, RVD Broecke - Acta Chirurgica Belgica, 2007 - Taylor & Francis
Oestrogens have a broad spectrum of physiological functions, ranging from regulation of the
menstrual cycle and reproduction to the modulation of bone, brain and lipid metabolism …
menstrual cycle and reproduction to the modulation of bone, brain and lipid metabolism …
Related searches
- breast cancer cell lines
- breast cancer aromatase inhibitors
- differential effects aromatase inhibitors
- breast cancer estrogen receptor
- breast cancer endocrine therapy
- efficacy and safety aromatase inhibitors
- breast cancer efficacy and safety
- breast cancer combined treatment
- breast cancer primary tumor
- aromatase overexpression estrogen receptor
- malignant changes estrogen receptor
- mcf 10a estrogen receptor
- endocrine therapy aromatase expression
- endocrine therapy primary tumor
- primary tumor aromatase expression
- breast cancer aromatase expression